News

ICON, the global provider of outsourced development services based in Dublin, Ireland, has further consolidated its strategic relationship with University College Dublin (UCD) by teaming up on a new graduate certificate in clinical research.

Eli Lilly has taken back from Transition Therapeutics’ an experimental diabetes drug for further development following the completion of proof-of-concept trials.

NHS England has put out a call to the public and NHS staff for input into an ongoing review of urgent care and emergency services.

Online patient network PatientsLikeMe has teamed up with inVentiv Health, the US-based provider of clinical development, commercialisation and consulting services, to accelerate patient recruitment for clinical trials.

Unpublished or misreported clinical trials whose data have entered the public domain should be made available to other “responsible” researchers for publication or formal correction through medical journals if the sponsors do not agree to set the record straight themselves, campaigners for data transparency propose.

Royalty Pharma’s bid to buy Elan Corp has now lapsed following votes at the latter’s emergency general meeting but it is still keen to work out a deal.

In its second landmark pharma case in the last few days, the US Supreme Court has decreed that pay-for-delay agreements between brand and generic drugmakers should indeed be subject to antitrust scrutiny.

A new polypill designed to reduce the risk of heart attacks and strokes in healthy patients has gone on sale in the UK over the internet this week, despite not being specifically licensed for this use.

AstraZeneca has confirmed that it will build a global R&D centre and new corporate headquarters at the Cambridge Biomedical Campus in the UK city.

AstraZeneca has linked up with the USA’s NGM Biopharmaceuticals to find new drugs for type 2 diabetes and obesity.

Cancer Research UK, the University of Manchester and AstraZeneca have signed two new deals on developing cancer drugs.

Another busy weekend for Celgene saw the firm get European approval for Revlimid as a treatment for a rare form of blood disease and present more promising data on its multiple myeloma drug pomalidomide.

Around a third of cervical cancer cases could be prevented every year in England if women were tested for human papilloma virus (HPV), researchers are claiming.

Nearly nine out of ten GPs in the UK say general practice ‘in crisis’ whilst half say they can no longer guarantee safe patient care.

Johnson & Johnson is expanding its position in prostate cancer by acquiring Aragon Pharmaceuticals in a deal that could be worth $1 billion.